The recent development of propofol (DIPRIVAN®)

Intensive Care Medicine, Supplement

Volumn 26, Issue 4, 2000, Pages

  Thompson, K A ^a   Goodale, D B ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EDETIC ACID; PROPOFOL;

ANESTHESIA INDUCTION; ARTICLE; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FOOD AND DRUG ADMINISTRATION; HUMAN; INFECTION; INTENSIVE CARE;

EID: 0034527359     PISSN: 09351701     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00003783     Document Type: Article

References (20)

1. The production and development of new drugs
2. Diprivan: A change in formulation
3. Postsurgical infections associated with an extrinsically contaminated intravenous anesthetic agent. California, Illinois, Maine, and Michigan
4. Postoperative infections at Texas hospital prompt drug warning
5. Postoperative infections traced to contamination of an intravenous anesthetic, propofol
6. Evaluation of the potential role of chelation therapy in treatment of low to moderate lead exposures
7. So much writing, so little science: A review of 37 years of literature on edetate sodium chelation therapy
8. Effects of chelation with EDTA and vitamin B therapy on nitric oxide-related endothelial vasodilator function
9. Fundamentals of emulsions
10. Perspective properties of EDTA
11. Unexpected outcome after two consecutive infusions of disodium EDTA in dairy cows
12. The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers
13. The influence of age on propofol pharmacodynamics
14. Trace element elimination during continuous sedation with propofol containing EDTA in critically ill patients